Clean Science and Technology Limited — PPTs, 14-05-2026: Investor Presentation

Clean Science and Technology showcased resilient EBITDA margins despite challenging market conditions for Q4 & FY26. Consolidated revenue for FY26 stood at INR 957 Cr (-1% YoY) with PAT at INR 230 Cr (-13% YoY). Q4 FY26 saw consolidated revenue of INR 249 Cr (-6% YoY) and PAT of INR 58 Cr (-22% YoY). The company achieved robust EBITDA margins (37.7% for FY26, 38.9% for Q4) driven by new product launches, especially HALS, which continues its sales momentum and contributed to a visible rebound in the base business.

Strategically, the company is focused on significant greenfield capex for new product series, adding new chemistries with a focus on high-value products, and expanding its specialty chemicals portfolio. FY26 saw a capex of ~INR 220 Cr, mainly for Clean Fino Chem Ltd. (CFCL), including the commercialization of India's largest HALS plant in March 2024. The Board approved a final dividend of INR 4 per share. With 61% of consolidated revenues from exports and a zero-debt status, CSTL emphasizes sustainable growth and R&D-driven innovation.